Literature DB >> 17038475

Treating rheumatic diseases in pregnancy: dos and don'ts.

M D Lockshin1.   

Abstract

This paper presents a critical appraisal of the current evidence and recommendations regarding the use of pharmaceuticals and biologicals in pregnancy. Clinical experience is often at variance with published recommendations as studies have not taken into account the differences in physiology in the various stages of gestation and between animal and human pregnancies. Physicians should bear in mind that pregnancy causes disruption in several organ systems; the effects of an intervention may depend on the stage of gestation; and some effects of interventions in pregnancy may not manifest until adulthood.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038475      PMCID: PMC1798378          DOI: 10.1136/ard.2006.058420

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register.

Authors:  Kimme L Hyrich; Deborah P M Symmons; Kath D Watson; Alan J Silman
Journal:  Arthritis Rheum       Date:  2006-08

2.  TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss.

Authors:  Jessica Berman; Guillermina Girardi; Jane E Salmon
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

3.  Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.

Authors:  Emily C Somers; Wendy Marder; Gregory M Christman; Vladimir Ognenovski; W Joseph McCune
Journal:  Arthritis Rheum       Date:  2005-09

Review 4.  Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.

Authors:  U Mahadevan; S Kane; W J Sandborn; R D Cohen; K Hanson; J P Terdiman; D G Binion
Journal:  Aliment Pharmacol Ther       Date:  2005-03-15       Impact factor: 8.171

Review 5.  Intrauterine exposure to diethylstilbestrol: long-term effects in humans.

Authors:  S H Swan
Journal:  APMIS       Date:  2000-12       Impact factor: 3.205

Review 6.  The complement system in the pathophysiology of pregnancy.

Authors:  Guillermina Girardi; Roberta Bulla; Jane E Salmon; Francesco Tedesco
Journal:  Mol Immunol       Date:  2006-01       Impact factor: 4.407

7.  Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.

Authors:  Jeffry A Katz; Christian Antoni; Gregory F Keenan; Deirdre E Smith; Stephen J Jacobs; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

8.  Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children.

Authors:  Gail Ross; Lisa Sammaritano; Ruth Nass; Michael Lockshin
Journal:  Arch Pediatr Adolesc Med       Date:  2003-04

9.  The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.

Authors:  Eliza F Chakravarty; Deanna Sanchez-Yamamoto; Thomas M Bush
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

10.  Anti-inflammatory and immunosuppressive drugs and reproduction.

Authors:  Monika Østensen; Munther Khamashta; Michael Lockshin; Ann Parke; Antonio Brucato; Howard Carp; Andrea Doria; Raj Rai; Pierluigi Meroni; Irene Cetin; Ronald Derksen; Ware Branch; Mario Motta; Caroline Gordon; Guillermo Ruiz-Irastorza; Arsenio Spinillo; Deborah Friedman; Rolando Cimaz; Andrew Czeizel; Jean Charles Piette; Ricard Cervera; Roger A Levy; Maurizio Clementi; Sara De Carolis; Michelle Petri; Yehuda Shoenfeld; David Faden; Guido Valesini; Angela Tincani
Journal:  Arthritis Res Ther       Date:  2006-05-11       Impact factor: 5.156

  10 in total
  1 in total

Review 1.  Pregnancy and rheumatic disease: "by the book" or "by the doc".

Authors:  Stephanie O Keeling; Anna E Oswald
Journal:  Clin Rheumatol       Date:  2008-11-06       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.